![](https://www.business-standard.com/assets/web-assets/images/Business_Standard_685x385.jpg)
Zydus Lifes gains after receiving approval from COFEPRIS for Bevacizumab biosimilar
Zydus Lifesciences rose 1.52% to Rs 1161.95 after the Mexican regulatory authority COFEPRIS (Federal Commission for the Protection Against Sanitary Risk) granted marketing approval to the company for Bhava, a Bevacizumab biosimilar. Bhava (Bevacizumab) is …